Thompson Siegel & Walmsley LLC raised its position in Mednax, Inc (NYSE:MD) by 95.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,170,741 shares of the company’s stock after buying an additional 1,062,584 shares during the period. Mednax accounts for about 1.6% of Thompson Siegel & Walmsley LLC’s holdings, making the stock its 6th largest position. Thompson Siegel & Walmsley LLC owned 2.32% of Mednax worth $131,048,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the company. State of Alaska Department of Revenue boosted its position in Mednax by 5.2% in the first quarter. State of Alaska Department of Revenue now owns 4,136 shares of the company’s stock worth $286,000 after buying an additional 204 shares during the last quarter. Mn Services Vermogensbeheer B.V. boosted its position in Mednax by 4.4% in the first quarter. Mn Services Vermogensbeheer B.V. now owns 2,428 shares of the company’s stock worth $158,000 after buying an additional 102 shares during the last quarter. Shell Asset Management Co. boosted its position in Mednax by 8.4% in the first quarter. Shell Asset Management Co. now owns 15,570 shares of the company’s stock worth $1,080,000 after buying an additional 1,200 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Mednax by 18.2% in the first quarter. Russell Investments Group Ltd. now owns 66,541 shares of the company’s stock worth $4,618,000 after buying an additional 10,227 shares during the last quarter. Finally, Sumitomo Mitsui Asset Management Company LTD boosted its position in Mednax by 9.7% in the first quarter. Sumitomo Mitsui Asset Management Company LTD now owns 6,980 shares of the company’s stock worth $484,000 after buying an additional 616 shares during the last quarter.

Shares of Mednax, Inc (NYSE:MD) traded down 1.69% on Friday, reaching $44.09. 764,780 shares of the company’s stock traded hands. The firm has a market cap of $4.06 billion, a P/E ratio of 14.04 and a beta of 0.40. Mednax, Inc has a one year low of $41.52 and a one year high of $72.13. The company’s 50-day moving average price is $47.62 and its 200 day moving average price is $58.78.

Mednax (NYSE:MD) last posted its quarterly earnings data on Friday, July 28th. The company reported $0.85 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.04. The firm had revenue of $843 million for the quarter, compared to analysts’ expectations of $849.49 million. Mednax had a net margin of 8.78% and a return on equity of 11.89%. The business’s quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter last year, the company posted $1.03 EPS. On average, equities analysts forecast that Mednax, Inc will post $3.31 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/09/02/thompson-siegel-walmsley-llc-acquires-1062584-shares-of-mednax-inc-md.html.

A number of brokerages have recently issued reports on MD. TheStreet cut Mednax from a “b-” rating to a “c+” rating in a report on Tuesday, May 16th. Stifel Nicolaus reduced their price objective on Mednax from $65.00 to $58.00 and set a “hold” rating for the company in a report on Thursday, May 25th. Mizuho reduced their price objective on Mednax from $64.00 to $58.00 and set a “neutral” rating for the company in a report on Tuesday, May 30th. ValuEngine cut Mednax from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Finally, BidaskClub upgraded Mednax from a “strong sell” rating to a “sell” rating in a report on Tuesday, June 13th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the company. Mednax currently has a consensus rating of “Hold” and an average price target of $63.00.

In other news, Director Md Pascal J. Goldschmidt sold 1,969 shares of the firm’s stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $57.57, for a total transaction of $113,355.33. Following the sale, the director now owns 18,072 shares in the company, valued at approximately $1,040,405.04. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 2.40% of the company’s stock.

About Mednax

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).

Institutional Ownership by Quarter for Mednax (NYSE:MD)

Receive News & Stock Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related stocks with our FREE daily email newsletter.